BERLIN, Germany, May 19, 2026
Bayer has announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) accepted regulatory applications for its investigational Factor XIa (FXIa) inhibitor asundexian for the prevention of ischemic stroke in patients following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). The FDA also granted Priority Review designation, highlighting the therapy’s potential to provide significant clinical improvement in secondary stroke prevention.
The regulatory submissions are supported by positive findings from the pivotal global Phase III OCEANIC-STROKE trial, which demonstrated that asundexian reduced ischemic stroke risk by 26% compared to placebo when combined with antiplatelet therapy, without increasing major bleeding risk. The development marks a major milestone for Bayer’s cardiovascular and cerebrovascular medicine portfolio and could potentially reshape long-term stroke prevention strategies worldwide.
Phase III OCEANIC-STROKE Trial Shows Strong Results
The multicenter, randomized, placebo-controlled OCEANIC-STROKE study enrolled more than 12,300 patients globally and evaluated once-daily oral asundexian 50 mg in patients who previously experienced a non-cardioembolic ischemic stroke or high-risk TIA. Researchers assessed the therapy in combination with standard antiplatelet treatment, focusing on prevention of recurrent ischemic stroke while minimizing bleeding complications.
According to Bayer, the trial successfully met its primary efficacy endpoint by significantly lowering recurrent ischemic stroke events compared with placebo. Importantly, the investigational therapy did not increase ISTH major bleeding, a key safety concern commonly associated with anticoagulant and antithrombotic therapies. Clinical experts believe the favorable balance between efficacy and bleeding safety could represent an important advancement in secondary stroke prevention.
Advertisement
Stroke remains one of the leading causes of death and long-term disability worldwide. Approximately 12 million people suffer a stroke each year, while nearly one in ten stroke survivors experiences another stroke within the first year despite currently available prevention strategies. Healthcare specialists continue emphasizing the urgent need for safer therapies capable of reducing recurrent cerebrovascular events without elevating bleeding risk.
FXIa Inhibition Represents Emerging Cardiovascular Innovation
Asundexian belongs to a new generation of investigational therapies targeting Factor XIa, a protein involved in pathological thrombosis formation. Scientists believe FXIa plays a significant role in abnormal clot formation responsible for stroke and vascular blockage while having a comparatively limited role in normal hemostasis required for wound sealing and bleeding control.
This unique mechanism has generated growing interest within the cardiovascular research community because selective FXIa inhibition may potentially reduce thrombotic events while minimizing bleeding complications often associated with traditional anticoagulants. Industry analysts view FXIa inhibitors as one of the most promising next-generation therapeutic classes in cardiovascular medicine.
Bayer stated that the FDA’s Priority Review designation underscores the seriousness of recurrent stroke risk and recognizes the potential clinical value of asundexian for patients with limited long-term prevention options. The company also confirmed that China’s Center for Drug Evaluation recently accepted the therapy’s marketing application and granted Priority Review designation, further accelerating global regulatory momentum.
Bayer Expands Cardiovascular and Stroke Medicine Pipeline
The latest regulatory milestone strengthens Bayer’s broader strategy of expanding innovation in cardiovascular and cerebrovascular medicine. The company continues investing heavily in therapies targeting stroke prevention, heart failure, chronic kidney disease, and other major cardiovascular disorders with high unmet medical need.
Industry experts believe the successful development of FXIa inhibitors could significantly influence future antithrombotic treatment paradigms by introducing safer long-term clot prevention approaches for millions of high-risk patients worldwide. Bayer is currently continuing global regulatory submissions for asundexian while advancing broader clinical research efforts in cardiovascular medicine.
The company emphasized that more than 90 million people worldwide live with the long-term consequences of stroke, creating substantial healthcare burdens and reinforcing the importance of developing safer, more effective secondary prevention therapies.
As precision cardiovascular medicine and targeted coagulation therapies continue advancing, Bayer’s asundexian program positions the company at the forefront of next-generation stroke prevention innovation with the potential to redefine future standards of care in cerebrovascular disease management.
Source: Bayer press release
